Can a new immune drug outsmart Hard-to-Treat tumors?
NCT ID NCT05592626
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, and the study aims to find safe doses and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- STAR0602 (also called Invikafusp alfa), an experimental immune-targeting drug, given alone or with chemotherapy (irinotecan or docetaxel)
- What this could lead to
- If this works, it could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial, so the drug may not work or may cause serious side effects. It is also a first-in-human study, meaning limited safety data exists.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Celebration
RECRUITINGCelebration, Florida, 34747, United States
-
Fred Hutchinson Cancer Center
ACTIVE_NOT_RECRUITINGSeattle, Washington, 98109, United States
-
Hospital Universitario Quirónsalud Madrid
RECRUITINGMadrid, Spain, 28223, Spain
-
Institute Gustave Roussy
RECRUITINGVillejuif, 94800, France
-
Instituto de Investigacion Sanitaria, INCLIVA
RECRUITINGValencia, 46010, Spain
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
-
National Institutes of Health
RECRUITINGBethesda, Maryland, 20892, United States
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
START Madrid FJD
RECRUITINGMadrid, 28040, Spain
-
Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville)
RECRUITINGNashville, Tennessee, 37203, United States
-
The Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Kansas Cancer Center
RECRUITINGKansas City, Kansas, 66160, United States
-
The University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
UC Davis Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGSacramento, California, 95817, United States
-
UT Health Mays Cancer Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
University of Miami Sylvester Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGMiami, Florida, 33136, United States
-
University of Wisconsin- Madison
RECRUITINGMadison, Wisconsin, 53792, United States
-
Vall d'Hebron Institute of Oncology
RECRUITINGBarcelona, Catalonia, 08035, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- A simple screening program could transform cancer aftercare
- Can a smart digital program restore sleep for cancer survivors?